We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+3.95%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$269M
AUM Growth
+$2.58M
Cap. Flow
-$7.75M
Cap. Flow %
-2.88%
Top 10 Hldgs %
61.2%
Holding
83
New
15
Increased
18
Reduced
11
Closed
33

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$9.5M
2
ASMB icon
Assembly Biosciences
ASMB
+$8.21M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$5.14M
4
IRIX icon
IRIDEX
IRIX
+$4.74M
5
ASND icon
Ascendis Pharma A/S
ASND
+$4.24M

Top Sells

Rank Stock Value
1
EVDY
Everyday Health, Inc.
EVDY
+$11.9M
2
AERI
Aerie Pharmaceuticals
AERI
+$8.7M
3
CEMP
Cempra, Inc.
CEMP
+$5.08M
4
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$3.9M
5
FOLD
Amicus Therapeutics
FOLD
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 77.17%
2 Technology 2.58%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$1.82B
– –
-25,000
Closed -$1.32M
AKTX
52
Akari Therapeutics
AKTX
$12.9M
– –
-29
Closed -$197K
ATRC icon
53
AtriCure
ATRC
$1.97B
– –
-66,186
Closed -$1.05M
AZN icon
54
AstraZeneca
AZN
$245B
– –
-15,000
Closed -$986K
BCRX icon
55
PUT
BioCryst Pharmaceuticals
BCRX
$2.24B
– –
-50,600
Closed -$223K
BMRN icon
56
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-30,000
Closed -$2.78M
CRBP icon
57
Corbus Pharmaceuticals
CRBP
$165M
– –
-2,710
Closed -$552K
CRDF icon
58
PUT
Cardiff Oncology
CRDF
$72.7M
– –
-1,111
Closed -$359K
RIGL icon
59
CALL
Rigel Pharmaceuticals
RIGL
$693M
– –
-10,000
Closed -$367K
RIGL icon
60
PUT
Rigel Pharmaceuticals
RIGL
$693M
– –
-1,190
Closed -$44K
SRPT icon
61
CALL
Sarepta Therapeutics
SRPT
$1.68B
– –
-39,700
Closed -$2.44M
SRPT icon
62
Sarepta Therapeutics
SRPT
$1.68B
– –
-50,000
Closed -$2.01M
THC icon
63
Tenet Healthcare
THC
$20.1B
– –
-32,809
Closed -$743K
XBI icon
64
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
– –
-150,000
Closed -$9.94M
MRTX
65
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-125,000
Closed -$826K
AGTC
66
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-10,193
Closed -$100K
AERI
67
CALL
DELISTED
Aerie Pharmaceuticals
AERI
– –
-59,600
Closed -$2.25M
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
– –
-40,000
Closed -$2.16M
PGNX
69
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-40,000
Closed -$253K
PGNX
70
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-432,370
Closed -$2.74M
GHDX
71
DELISTED
Genomic Health, Inc.
GHDX
– –
-72,100
Closed -$2.08M
EHIC
72
DELISTED
eHi Car Services Limited
EHIC
– –
-58,827
Closed -$603K
TSRO
73
DELISTED
TESARO, Inc.
TSRO
– –
-22,700
Closed -$2.27M
DXTR
74
DELISTED
Dextera Surgical Inc.
DXTR
– –
-128,958
Closed -$242K
CEMP
75
DELISTED
Cempra, Inc.
CEMP
– –
-210,000
Closed -$5.08M
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2016 Portfolio in Review

As of Q4 2016, Acuta Capital Partners held 83 positions worth $269M, up 0.97% from $266M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Acuta Capital Partners's Q4 2016 filing shows 15 new, 18 increased, 11 reduced and 33 closed positions. Its largest new stake was Aclaris Therapeutics: 372,753 shares worth $10.1M. The largest sale was Everyday Health, Inc., an estimated $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.

  • Acuta Capital Partners's largest Q4 2016 buy was Aclaris Therapeutics: 372,753 shares worth $10.1M.
  • Acuta Capital Partners added most to Assembly Biosciences in Q4 2016, an estimated $8.21M increase.
  • Acuta Capital Partners's biggest Q4 2016 reduction was Aerie Pharmaceuticals, cutting an estimated $8.7M.
  • Acuta Capital Partners fully exited Everyday Health, Inc. in Q4 2016, selling an estimated $11.9M.
  • Acuta Capital Partners's ten largest holdings make up 61% of its $269M portfolio in Q4 2016.
  • Acuta Capital Partners opened 15 new positions and closed 33 in Q4 2016.
  • Acuta Capital Partners's portfolio value rose 0.97% quarter-over-quarter to $269M.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.